{
    "clinical_study": {
        "@rank": "52048", 
        "acronym": "JASMINE_205", 
        "arm_group": [
            {
                "arm_group_label": "Placebo"
            }, 
            {
                "arm_group_label": "stannsoporfin 3.0 mg/kg"
            }, 
            {
                "arm_group_label": "stannsoporfin 4.5 mg/kg"
            }
        ], 
        "brief_summary": {
            "textblock": "The objectives of this follow up study are to evaluate the long-term effects of\n      stannsoporfin (Stanate) on the health, growth, and development of patients who received a\n      single dose of stannsoporfin with PT used to treat hyperbilirubinemia compared with patients\n      in the control (placebo plus PT) group in clinical trial 64,185-204."
        }, 
        "brief_title": "Follow up Study of Patients Having Participated in Clinical Trial 64,185-204", 
        "condition": "Evaluate the Long-term Health Effects of Stannsoporfin on Patients From Clinical Trial 64,185-204.", 
        "detailed_description": {
            "textblock": "Outcomes will be based on the following variables:\n\n      Reported AEs and SAEs Hearing assessments Developmental assessments"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who received IMP (stannsoporfin or placebo) in clinical trial 64,185-204\n\n          -  Parents or guardians have given written informed consent to participate"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "52 Months", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "patients who received a single dose of trial medication in clinical trial 64,185-204."
            }
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02000830", 
            "org_study_id": "64,185-205"
        }, 
        "intervention": {
            "arm_group_label": [
                "stannsoporfin 3.0 mg/kg", 
                "stannsoporfin 4.5 mg/kg"
            ], 
            "intervention_name": "stannsoporofin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Tin mesoporphyrin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "stannsoporfin", 
        "lastchanged_date": "November 26, 2013", 
        "number_of_groups": "3", 
        "official_title": "A 48-52 Month Blinded-Outcomes Follow up Study of Patients Having Received Stannsoporfin or Placebo in Clinical Trial 64,185-204", 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Reported adverse events (AEs)", 
            "safety_issue": "Yes", 
            "time_frame": "48-52 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02000830"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Conventional audiometry will be performed by a qualified specialist. Any findings from a failed conventional audiology examination will be recorded", 
                "measure": "Hearing assessments", 
                "safety_issue": "Yes", 
                "time_frame": "48 - 52 month"
            }, 
            {
                "description": "The Mullen Scales of Early Learning examination has been selected for its standardized measurement of developmental skills in multiple domains (gross motor, visual reception, fine motor, expressive language, and receptive language). Testing will be done at visits 1 and 2 by a healthcare individual trained to administer the test. The Mullen raw scores, T-scores, and age equivalents will be recorded.", 
                "measure": "Developmental assessments", 
                "safety_issue": "Yes", 
                "time_frame": "48 - 52 month"
            }
        ], 
        "source": "InfaCare Pharmaceuticals Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "InfaCare Pharmaceuticals Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}